Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials

Highlights:

  • Clear and constructive guidance received from pre-IND meetings with the FDA Office of Neuroscience for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes
  • Positive outcome is an important milestone that enables Neuren to proceed with IND applications for FDA clearance to start the trials
  • Subject to...

Read more: Positive FDA meetings enable Neuren to proceed with INDs for three Phase 2 trials

More Articles …

  1. Australia's original prolonged-release melatonin now available over the counter at pharmacies
  2. With 681 Million 5G Handsets Set to Ship in 2022, Mobile Device Vendors Scramble for Differentiation
  3. Maastricht University research finds that mealworm protein is as beneficial as milk protein
  4. 100th Elekta Unity MR-Linac goes to St George's Hospital in New Zealand
  5. Mineração Vale Verde completes construction at the Serrote copper-gold mine ahead of schedule and under budget
  6. Acclime consolidates its expansion to Australia with the rebranding of CoSec Corporate Services
  7. GROHE and American Standard announce winners of the Asia Pacific Property Awards 2021-22
  8. Singapore-based Impact Investor Heritas Capital Announces US$60M First Close of Heritas Growth Fund III to Back Asian Emerging Champions Driving Sustainable Covid-19 Recovery
  9. Fideuram - Intesa Sanpaolo Private Banking and REYL & Cie Receive Regulatory Approval to enter into Strategic Partnership
  10. 'Vegeta' Seasoning up the competition in Australia's Food Sport Arena